Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

New TeaCrine® Clinical Trial Illustrates Increased Potency When Combined With Caffeine

Compound Solutions
Posted on: 31 Jul 17

CARLSBAD, Calif., July 31, 2017 /PRNewswire/ -- Compound Solutions, Inc., exclusive global distributor of patent-protected TeaCrine®, today announced several groundbreaking findings from a new human clinical trial.

Performed at the University of Tennessee and the University of Memphis with renowned health, pharmaceutical, and cardiorespiratoroy/metabolic research programs, the robust randomized, double-blind, placebo-controlled, four-arm crossover study set out to explore the pharmacokinetics and safety of TeaCrine® at multiple doses, and when administered with caffeine. The findings showed: 1) consuming TeaCrine® with caffeine enhanced TeaCrine's bioavailability and potency, 2) combining the two ingredients showed an excellent safety profile, as evaluated by repeated measurements across a broad spectrum of clinical safety markers including heart rate and blood pressure (i.e. both of which were unaffected by co-administration).

Previous human research conducted at the Center for Applied Health Sciences showed that TeaCrine® increased feelings of energy, reduced fatigue, and had strong effects on improving focus, concentration, motivation to exercise and libido. This new study not only validates the prior study's findings, but it also shows the addition of caffeine augments these benefits by improving TeaCrine®'s bioavailability (increased peak levels and total concentration in the blood over time).

Matt Titlow, CEO of Compound Solutions, said, "We're proud to prove clinically what many have noted anecdotally: caffeine and TeaCrine® are a complementary, dynamic combination."

Leading global sport nutrition brands such as Cellucor®, MyProtein®, Performix®, Beast®, Ronnie Coleman Signature Series®, Ghost®, ProSupps®, MuscleTech®, MAN®, Finaflex®, Nutrex® and others currently in development have all licensed the IP-protected ingredient and effectively paired it with caffeine, maximizing the benefits for end-users. Titlow added, "TeaCrine® is a mainstay in one of the most innovative categories in all of dietary supplements—sports nutrition. But TeaCrine® can do much more, and the next five months will demonstrate a very significant expansion into the gaming/esports, cognitive performance, energy drink and biohacking categories. The TeaCrine®-Caffeine combination is becoming foundational in the energy and focus categories."

The study results, combined with previous TeaCrine® research, further indicate that TeaCrine® is delivering a mental and performance edge without the crash or jitters associated with caffeine alone.

TeaCrine® now appears in nearly 200 innovative products that recognize the importance of safety, regulatory compliance, and reliable, science-backed and clinically evaluated ingredients. The new data sets the stage for a rapid rise into the nootropic, sports nutrition, biohacking & energy drink categories.

Reference:  He Hui, Ma Dejian, Crone Laura Brooks, et al. Assessment of the Drug–Drug Interaction Potential Between Theacrine and Caffeine in Humans. Journal of Caffeine Research. July 2017, ahead of print.  https://doi.org/10.1089/jcr.2017.0006

About Compound Solutions, Inc.

Compound Solutions, Inc. is the go-to company representing and distributing unique, patented nutraceutical ingredients for the sports nutrition, functional food and nutritional supplement markets. Compound Solutions is the exclusive global supplier of TeaCrine®.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 31/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.